GSK plc Amends Nkarta, Inc. Filing

TL;DR

GSK plc filed an amendment for Nkarta, Inc. - ownership details updated.

AI Summary

GSK plc has amended its Schedule 13D filing regarding Nkarta, Inc. on March 28, 2024. The filing indicates a change in beneficial ownership, though specific new holdings or dollar amounts are not detailed in this excerpt. This amendment is the second for GSK plc concerning Nkarta, Inc.

Why It Matters

This filing update from GSK plc suggests a potential shift in their investment or strategic interest in Nkarta, Inc., which could impact Nkarta's stock performance and future development plans.

Risk Assessment

Risk Level: medium — Changes in major shareholder filings can indicate shifts in strategy or potential future actions that could affect the company's stock.

Key Players & Entities

• GSK plc (company) — Filing party
• Nkarta, Inc. (company) — Subject company
• Victoria A. Whyte (person) — Mentioned in filing

FAQ

Key Financial Figures

• $0.0001 — ame of Issuer) Common Stock, Par Value $0.0001 (Title of Class of Securities) 65487U
• $0 — f the shares of common stock, par value $0.0001, of Nkarta, Inc. per share (the "I

Filing Documents

• gsk-sc13da_032524.htm (SC 13D/A) — 50KB
• 0001999371-24-004134.txt ( ) — 51KB

Security

Item 1. Security and Issuer . This Amendment No. 2 to Schedule 13D (this "Statement") amends and supplements the statement on Schedule 13D originally filed on July 22, 2020, as subsequently amended by Amendment No. 1 filed on May 13, 2022 (the "Schedule 13D") with respect to the shares of common stock, par value $0.0001 per share (the "Common Stock") of Nkarta, Inc., a Delaware corporation (the "Issuer"). The Issuer's principal executive offices are located at 1150 Veterans Boulevard, South San Francisco, CA 94080. This amendment is filed to disclose a change in beneficial ownership of the Reporting Person as a result of purchase of shares of Common Stock and an increase in the Issuer's Common Stock outstanding. Unless otherwise indicated, each capitalized term used but not defined herein shall have the meaning assigned to such term in the Original Schedule 13D.

Identity and Background

Item 2. Identity and Background. The response set forth in Item 2 of the Schedule 13D of the Schedule 13D is hereby amended by (i) deleting Schedule 1 in its entirety and replacing it with Schedule 1 attached and (ii) replacing Item 2 with the following: This Statement is being filed on behalf of GSK, a public limited company incorporated under the laws of England and Wales. GSK and its subsidiaries constitute a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together, with its principal offices located at 980 Great West Road, Brentford, Middlesex TW8 9GS, England. Set forth in Schedule 1 to this Statement are the name, business address and present principal occupation or employment and citizenship of each executive officer and director of GSK. The Ordinary Shares are held directly by GGL and GSK EI. During the last five years prior to the date hereof, neither GSK nor, to the best knowledge of GSK, any of the other persons with respect to whom information is given in response to this Item 2 has been convicted in a criminal proceeding or been a party to a civil proceeding ending in a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws, or finding any violation with respect to such laws.

Interest in Securities of the Issuer

Item 5. Interest in Securities of the Issuer. The response set forth in Item 5(a), (b) and (c) of the Schedule 13D is hereby amended by deleting the previous response in its entirety and replacing it with the following: (a) GSK plc beneficially owns 3,161,432 shares of Common Stock, which represents 4.5% of the Common Stock outstanding, based on 70,191,296 of the Issuer's shares outstanding as of March 27, 2024, upon the closing of the Issuer's public offering of Common Stock, as reported in the Issuer's Prospectus Supplement. (b) GSK plc has the sole power to vote or direct the vote, and the sole power to dispose or to direct the disposition of all 3,161,432 shares of Common Stock described in Item 5(a) above. (c) The Reporting Person ceased to be the beneficial owner of more than five percent of the Common Stock on March 27, 2023. Therefore, this is the final amendment to the Statement and an exit filing for the Reporting Person. Cusip No. 65487U 10 8 13D/A2 Page 4 of 7 SIGNATURE After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. Date: March 28, 2024 GSK plc By: /s/ Victoria A. Whyte Name: Victoria A. Whyte Title: Authorized Signatory Cusip No. 65487U 10 8 13D/A2 Page 5 of 7 Schedule 1 Name Citizenship Board of Directors Sir Jonathan Symonds CBE 980 Great West Road Brentford Middlesex TW8 9GS, England Chair and Company Director British Emma Walmsley 980 Great West Road Brentford Middlesex TW8 9GS, England Executive Director and Chief Executive Officer British Julie Brown 980 Great West Road Brentford Middlesex TW8 9GS, England Company Director and Chief Financial Officer British Elizabeth McKee Anderson 980 Great West Road Brentford Middlesex TW8 9GS, England Company Director US Charles Bancroft 980 Great West Road Brentford Middlesex TW8 9G

View Full Filing

View this SC 13D/A filing on SEC EDGAR